AGIOS PHARMACEUTICALS INC. - COMMON STOCK

25,76

04-апреля-25 16:45:00

15 мин. задержка

Акции

-1,95

-7,04%

Сегодняшний диапазон

25,26 - 27,86

ISIN

N/A

Источник

NASDAQ

NetDania - New 12 months Low: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

04 апр 2025 09:58:04 Источник NetDania Notify
NetDania - New 12 months Low: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

01 апр 2025 13:49:16 Источник NetDania Notify
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

05 мар 2025 17:52:45 Источник Nasdaq GlobeNewswire
Agios to Present at Upcoming Investor Conferences

04 мар 2025 07:00:00 Источник Nasdaq GlobeNewswire
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

20 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

13 фев 2025 06:31:00 Источник Nasdaq GlobeNewswire
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

13 фев 2025 06:30:00 Источник Nasdaq GlobeNewswire
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

06 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

13 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire
FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

08 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

03 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

18 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

08 дек 2024 12:40:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

11 ноя 2024 09:45:31 Источник NetDania Notify
NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

08 ноя 2024 09:55:39 Источник NetDania Notify
NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

07 ноя 2024 14:59:27 Источник NetDania Notify
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

05 ноя 2024 09:05:00 Источник Nasdaq GlobeNewswire
Agios Reports Business Highlights and Third Quarter 2024 Financial Results

31 окт 2024 06:30:00 Источник Nasdaq GlobeNewswire
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

23 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

17 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.